MiMedx Group, Inc.
NASDAQ:MDXGBiotechnology
+$0.08 today
- Market cap
- $464.04M
- Beta
- 1.46
- P/E (TTM)
- 17.8
- EPS (TTM)
- $0.21
Volume 1.51M
Average 1.55M
MDXG Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MiMedx Group, Inc.NASDAQ: MDXG
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation turns negative
Q1 FY2026 stock-based compensation was -$1.7M, compared with $4.26M a year earlier. Trailing-twelve-month stock-based compensation was $14.7M. Over 3 fiscal years it compounded at +13.1% a year.
Context
- Stock-based compensation amounted to 3.9% of revenue in FY2025, down 0.9 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly stock-based compensation holds near -$1.7M or moves back toward the trailing-twelve-month quarterly average of $3.68M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 16.4M USD
- Year-over-year change
- -3.2%
- 4-year CAGR
- +3.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.4M | -3.2% |
| FY2024 | 2024-12-31 | 16.93M | -0.2% |
| FY2023 | 2023-12-31 | 16.96M | +49.7% |
| FY2022 | 2022-12-31 | 11.33M | -20.0% |
| FY2021 | 2021-12-31 | 14.16M | — |
Stock-Based Compensation vs competitors
How MDXG compares with its peers on the latest reported figures
- MDXG's LTM Mar 2026 stock-based compensation of $14.7M is the largest of the 8 companies compared; the peer median is $4.71M.
- Its year-over-year change of -12.8% is the 5th highest of 8, against a peer median of -11.5%.
- Stock-based compensation amounts to 3.8% of revenue for MDXG, versus a peer median of 15.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.7M | -12.8% | +13.1% | 3.8% | |
| LTM Mar 2026 | $13.57M | +17.6% | +26.6% | 2.6% | |
| LTM Dec 2025 | $10.38M | -11.5% | -13.2% | 39.1% | |
| LTM Mar 2026 | $7.93M | -41.7% | +10.8% | 11.0% | |
| LTM Mar 2026 | $4.71M | -8.3% | +3.5% | 31.8% | |
| LTM Jun 2026 | $3.91M | -7.6% | — | — | |
| LTM Mar 2026 | $2.91M | -16.2% | +16.9% | 20.1% | |
| LTM Mar 2026 | $442.14K | -91.0% | -35.7% | 0.4% | |
| Peer median (excluding MDXG) | $4.71M | -11.5% | +7.1% | 15.5% | |
Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.3M) | (19.95M) | 67.44M | 42M | 48.58M |
| Depreciation & Amortization | 5.18M | 4.05M | 3.43M | 6.04M | 14.88M |
| Deferred Income Tax | 0 | 0 | (37.8M) | 12.47M | 8.71M |
| Stock-Based Compensation | 14.16M | 11.33M | 16.96M | 16.93M | 16.4M |
| Change in Working Capital | (19.35M) | (8.01M) | (18.42M) | (5.43M) | (22.98M) |
| Accounts Receivables | (10.62M) | (5.94M) | (12.24M) | (2.55M) | (26.39M) |
| Inventory | (1.41M) | (1.79M) | (7.84M) | (2.36M) | (1.53M) |
| Accounts Payables | (159K) | 839K | 783K | (1.41M) | 2.12M |
| Other Working Capital | (7.17M) | (1.12M) | 876K | 885K | 2.83M |
| Other Non-Cash Items | 10.33M | 6.03M | (4.83M) | (5.81M) | 8.42M |
| Operating Cash Flow | (1.98M) | (17.89M) | 26.78M | 66.2M | 74M |
| Capital Expenditures | (3.22M) | (1.51M) | (1.99M) | (1.68M) | (1.03M) |
| Acquisitions (Net) | 0 | 24K | 0 | (7.86M) | (3.76M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (177K) | (1.15M) | (168K) | (38K) | 0 |
| Investing Cash Flow | (3.4M) | (2.66M) | (2.16M) | (9.58M) | (6.89M) |
| Debt Repayment | (38K) | (41K) | (52K) | (31.72M) | (1M) |
| Common Stock Issued | 0 | 651K | 997K | 0 | 0 |
| Common Stock Repurchased | (4.75M) | (1.19M) | (9.52M) | (2.64M) | (3.12M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.44M | (41K) | 9.46M | 159K | (1.29M) |
| Financing Cash Flow | (3.35M) | (580K) | (8.57M) | (34.2M) | (5.41M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.73M) | (21.13M) | 16.05M | 22.42M | 61.71M |
| Free Cash Flow | (5.2M) | (19.41M) | 24.79M | 64.52M | 72.97M |
MiMedx Group, Inc.
NASDAQ:MDXG
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.